MelliCell, Inc.
Madhumita Basu currently serves as Principal Scientist in Target Discovery at MelliCell, Inc., with additional roles as Editorial Board Member for Communications Biology-Nature and Topic Editor for Frontiers in Genetics. Madhumita Basu is part of the Leadership Team for the Cardiovascular & Diabetes Interest Group at the American Diabetes Association. Previous positions include Assistant Professor and Postdoctoral Research Scientist at Nationwide Children's Hospital, as well as Research Assistant Professor at The Ohio State University. Educational qualifications include a Ph.D. in Human Molecular Genetics from the University of Calcutta, along with a Master's in Biochemistry and a Bachelor's in Chemistry from the same institution. Madhumita Basu also has experience as a Senior and Junior Research Fellow during early research career stages in India.
This person is not in any teams
MelliCell, Inc.
MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of therapeutic targets and leads, while reducing the time and money required for efficacy screening. It efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes of mature fat cells in adults. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts diabetes better than obesity per se. The products we develop will treat obesity and diabetes by shrinking fat cell size and by preventing compromised metabolism in enlarged cells. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.